# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
1 | 08-07-2025 | 06-30-2025 | 10-Q | |
2 | 05-08-2025 | 03-31-2025 | 10-Q | |
3 | 03-11-2025 | 12-31-2024 | 10-K | |
4 | 11-07-2024 | 09-30-2024 | 10-Q | |
5 | 08-08-2024 | 06-30-2024 | 10-Q |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Truist Securities analyst Joon Lee initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating and announces ...
Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company d...
Rapport Therapeutics' RAP-219 cut seizures significantly in a Phase 2a trial, with strong results and a favorable safety pr...